

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.39)

Application Number		10568367
Filing Date		2004-06-18
First Named Inventor	GARCIA-ECHEVERRIA et al.	
Art Unit	1614	
Examiner Name		
Attorney Docket Number	329105-US-PC7	

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3432493		1966-03-11	SHORT et al.	
	2	6235745		2001-06-22	DAVIS et al.	
	3	6693326		2003-07-15	BRADBURY et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	EP1054004	EP	A1	2000-11-22	YAMANOUCHI PHARMACEUTICAL CO., LTD., JAPAN		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10568367
Filing Date	2004-08-18
First Named Inventor	GARCIA-ECHEVERRIA et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	32910B-US-PCT

2	EP1184376	EP	B1	2005-02-02	YAMANOUCHI PHARMACEUTICAL CO. LTD., JAPAN	<input type="checkbox"/>
3	WO1997/019065	WO	A1	1997-05-29	CELLTECH THERAPEUTICS LIMITED	<input type="checkbox"/>
4	WO1999/050250	WO	A1	1999-10-07	JANSSEN PHARMACEUTICA N.V.	<input type="checkbox"/>
5	WO2000/012486	WO	A1	2000-03-09	ZENECA LIMITED	<input type="checkbox"/>
6	WO2000/030101	WO	A1	2000-07-06	ASTRAZENECA UK LIMITED	<input type="checkbox"/>
7	WO2001/060816	WO	A1	2001-08-23	AMGEN INC.	<input type="checkbox"/>
8	WO2001/064654	WO	A1	2001-09-07	ASTRAZENECA AB	<input type="checkbox"/>
9	WO2001/054655	WO	A1	2001-09-07	ASTRAZENECA AB	<input type="checkbox"/>
10	WO2001/054656	WO	A1	2001-09-07	ASTRAZENECA AB	<input type="checkbox"/>
11	WO2003/018021	WO	A1	2003-03-06	AMGEN INC.	<input type="checkbox"/>
12	WO2003/030909	WO	A1	2003-04-17	BAYER CORPORATION	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566367
Filing Date		2004-08-18
First Named Inventor	GARCIA-ECHEVERRIA et al.	
Art Unit	1614	
Examiner Name		
Attorney Docket Number	32910B-US-PCT	

13	WO2003/063794	WO	A2	2003-08-07	RIGEL PHARMACEUTICALS, INC.	<input type="checkbox"/>
14	WO2003/066601	WO	A1	2003-08-14	SMITHKLINE BEECHAM CORPORATION	<input type="checkbox"/>
15	WO2003/078404	WO	A1	2003-09-25	NOVARTIS AG	<input type="checkbox"/>
16	WO2003/095448	WO	A1	2003-11-20	BAYER PHARMACEUTICALS CORPORATION	<input type="checkbox"/>
17	WO2004/002964	WO	A1	2004-01-06	YAMANOUCHI PHARMACEUTICAL CO., LTD.	<input type="checkbox"/>
18	WO2004/074244	WO	A2	2004-09-02	SMITHKLINE BEECHAM CORPORATION	<input type="checkbox"/>
19	WO2004/080960	WO	A1	2004-09-23	NOVARTIS AG	<input type="checkbox"/>
20	WO2005/016894	WO	A1	2005-02-24	NOVARTIS AG	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T*
	1	GHONEIM, Khadiga M , "Synthesis and Evaluation of Some 2-, 4-, and 2,4- Di-substituted-6-methylpyrimidine Derivatives for Antimicrobial Activity", Journal of the Indian Chemical Society, 1986 Vol. 63 No. 10 p. 914-917.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10568367
Filing Date		2904-08-18
First Named Inventor	GARCIA-ECHEVERRIA et al.	
Art Unit	1614	
Examiner Name		
Attorney Docket Number	329108-US-PCT	

2	GHOSH, D., "2,4-Bis(Arylamino)-6-Methyl Pyrimidines as Antimicrobial Agents", Journal of the Indian Chemical Society, 1981 Vol. 58 No. 5 p. 512-513.	<input type="checkbox"/>
3	GHOSH, D., "2,4-Bis(Arylamino)-6-Methylpyrimidines as Antimicrobial Agents", Journal of Medicinal Chemistry, 1967 Vol. 10 No. 5 p. 974-975.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE	
Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 801.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10568367
Filing Date	2004-08-18
First Named Inventor	GARCIA-ECHEVERRIA et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	32910B-US-PCT

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2008-06-22
Name/Pnnt	Mark Baron	Registration Number	48,150

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**